Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection.
We describe a distinctive mucocutaneous eruption that occurred in 14 of 20 (70%) patients with human immunodeficiency virus infection while they were being treated with a new therapeutic agent, 2'3'-dideoxycytidine. A maculopapular eruption developed in these patients on day 10 or 11 of treatment. Seven of 14 patients, especially those receiving higher-dose therapy, also had systemic symptoms. In addition, oral ulcers developed in 9 of 14 patients on days 4 to 6 of therapy. The occurrence of the cutaneous and oral lesions correlated with dose, route, and schedule of administration of 2'3'-dideoxycytidine. In most instances the mucocutaneous lesions resolved even with continuation of therapy.
McNeely
M C
MC
Dermatology Branch, National Institutes of Health, Bethesda, MD 20892.
Yarchoan
R
R
Broder
S
S
Lawley
T J
TJ
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004341:Drug Evaluation; D015488:HIV Antigens / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000209:etiology*; D006377:T-Lymphocytes, Helper-Inducer / Q000378:metabolism; D014456:Ulcer / Q000209:etiology; D016047:Zalcitabine / Q000009:adverse effects / Q000031:analogs & derivatives*
D015488:HIV Antigens; D016047:Zalcitabine; C050624:2',3'-dideoxycytidinene